- Spain CIMA (Spanish): search for “aceclofenac” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- Hypersensitivity to aceclofenac or excipients
- Aspirin- or NSAID-induced asthma, bronchospasm, rhinitis or urticaria
- Active bleeding or bleeding disorders
- Previous NSAID-related gastrointestinal bleeding or perforation
- Active or recurrent peptic ulcer or hemorrhage
- Established heart failure (NYHA class II–IV), ischemic heart disease, peripheral arterial disease or cerebrovascular disease
- Severe hepatic or kidney impairment
- Third trimester of pregnancy
Dosing: Adult
- Pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: 100 mg twice daily (morning and evening); maximum 200 mg/day
- Mild to moderate hepatic impairment: Start at 100 mg/day
Dosing: Altered kidney function
Aceclofenac is a nonsteroidal anti-inflammatory drug (NSAID) partly converted to diclofenac; about two-thirds of a dose leaves in urine as metabolites. NSAIDs can precipitate kidney failure in at-risk patients. The European label needs no dose change in mild kidney impairment (with caution), asks for the lowest dose and regular kidney monitoring in mild to moderate impairment, and contraindicates it in severe impairment. It has no US FDA label.
Kidney function measure: The SmPC grades kidney impairment as mild, moderate or severe without numbers; bands map 'severe' to creatinine clearance (CrCl) <30 mL/min.
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 100 mg twice daily; maximum 200 mg/day (SmPC). Mild impairment: no dose change but caution.
- CrCl 30–59 mL/min
- Mild to moderate impairment: lowest effective dose with surveillance and regular kidney function checks (SmPC). Avoid with volume depletion or diuretics where possible. Short courses only; hold during intercurrent illness or volume depletion (sick-day rule; KDIGO 2024).
- CrCl 15–29 mL/min
- Severe kidney impairment: contraindicated (SmPC; no numeric threshold). Our mapping of 'severe' to CrCl <30 is a judgment.
- CrCl <15 mL/min (not on dialysis)
- Severe kidney impairment: contraindicated (SmPC; no numeric threshold). Our mapping of 'severe' to CrCl <30 is a judgment.
- Hemodialysis (intermittent)
- Contraindicated (severe kidney impairment; SmPC).
- Peritoneal dialysis
- Contraindicated (severe kidney impairment; SmPC). NSAIDs hasten loss of residual kidney function.
- CRRT
- Contraindicated; NSAIDs worsen acute kidney injury.
- Dialyzable? Not stated (over 99.7% protein-bound).
- Monitoring Kidney function regularly in mild to moderate impairment, heart failure, liver disease, diuretic use, after major surgery and in older adults; blood pressure; potassium with potassium-sparing diuretics; gastrointestinal bleeding (SmPC 4.4). Check creatinine and potassium within 1–2 weeks of starting in CKD or with an ACE inhibitor, ARB, mineralocorticoid receptor antagonist (MRA) or diuretic; avoid the NSAID + ACE inhibitor/ARB + diuretic ("triple whammy") combination and long-term use in CKD.
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: MPA (Sweden) product information (March 24, 2023). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not established in children and adolescents (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 100 mg
- Controlled-release tablet: 200 mg
- Softgel capsule: 100 mg
- Sustained-release tablet: 200 mg
- Tablet: 100 mg
Registered products in the Philippines
17 products registered with the Food and Drug Administration (FDA) Philippines list Aceclofenac as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products17
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Aceclo-XAceclofenac | 100mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Teramedix Pharma Trading Inc. | DR-XY47814 | Mar 14, 2027 | |
AceclomedAceclofenac | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Acme Formulation Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-12160 | Jun 24, 2027 | |
AcedocareAceclofenac | 100 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 100's) | Rx | Mediwin PharmaceuticalsIndia | Cyden Medicale Trading Inc.Importer: Ambica International Corporation | DRP-4678-02 | Sep 6, 2028 | |
ACF-100Aceclofenac | 100 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | Rx | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-4678 | Sep 6, 2028 | |
AfenaxAceclofenac | 100 mg Film-Coated TabletClear PVDC/ Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-9980 | Feb 18, 2028 | |
AirtalAceclofenac | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 20's, 40's, 50's and 100's) | Rx | Industrias Farmaceuticas Almirall, S.A.Spain | Pacific Healthcare Philippines, Inc. | DR-XY37620 | Mar 4, 2031 | |
CeclofamAceclofenac | 100mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) (Box of 30’s) | Rx | ACME Formulations Pvt. Ltd.India | JJJ Pharmaceutical Marketing Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12160-01 | Jun 24, 2027 | |
ClanzaAceclofenac | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Korea United Pharm. Inc.Republic of Korea | One Pharma Marketing Inc. | DR-XY30590 | Mar 25, 2031 | |
Clanza CRAceclofenac | 200 mg Controlled-Release TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Korea United Pharm. Inc.Republic of Korea | One Pharma Marketing Inc. | DR-XY39980 | Sep 1, 2031 | |
Clanza SAceclofenac | 100 mg Softgel CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Korea United Pharm. Inc.Republic Of Korea | One Pharma Marketing Inc. | DR-XY34671 | Mar 26, 2032 | |
DiclotolAceclofenac | 100 mg Film-Coated TabletAlu/Alu Blister Pack X 10'S (Box of 50's); Physician's Sample Alu/Alu Blister Pack X 1'S (Box of 1's ) | Rx | Kusum Healthcare Private LimitedIndia | Kusum Healthcare Private Limited Branch Office | DR-XY42297 | Mar 6, 2031 | |
DolowinAceclofenac | 100mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's | Rx | MICRO LABS LIMITEDIndia | BROWN & BURK PHILIPPINES, INC. | DR-XY41396 | Nov 23, 2027 | |
Dolowin SRAceclofenac | 200 mg Sustained Release TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY41012 | Jul 9, 2027 | |
FenaxinAceclofenac | 100 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | Rx | Mediwin PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4678-01 | Sep 6, 2028 | |
SofenacAceclofenac | 100 mg Softgel CapsulePVC/Aluminum Blister Pack x 10's (Box of 30's and 100's) | Rx | Phil Inter Pharma Co., LtdVietnam | Lealmeds Pharmaceutical Inc. | DR-XY43694 | Sep 3, 2029 | |
ZerodolAceclofenac | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | IPCA Laboratories Ltd.India | Blue Global (FZE) | DRP-9902 | Nov 27, 2029 | |
Zerodol-CRAceclofenac | 200 mg Controlled-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ipca Laboratories LimitedIndia | Importer: Blue Global (FZE) | DRP-12486 | Feb 5, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Other NSAIDs, COX-2 inhibitors | Avoid | More gastrointestinal bleeding. | Do not combine. |
| High-dose methotrexate | Avoid | Methotrexate toxicity. | Avoid. |
| Lithium, digoxin | Adjust or monitor | Higher levels. | Avoid unless levels are monitored frequently. |
| ACE inhibitors or ARBs plus a diuretic ("triple whammy") | Avoid | Acute kidney injury, hyperkalemia. | Avoid the triple combination; if unavoidable, hydrate and check creatinine and potassium within 1 week. |
| ACE inhibitors, ARBs, mineralocorticoid receptor antagonists or diuretics (single agent) | Adjust or monitor | Acute kidney injury; hyperkalemia in CKD. | Hydrate; monitor creatinine and potassium. |
| Cyclosporine, tacrolimus, low-dose methotrexate | Adjust or monitor | Kidney toxicity. | Monitor kidney function. |
| Warfarin, antiplatelets, corticosteroids, SSRIs | Adjust or monitor | More gastrointestinal bleeding. | Use with caution. |
| Potassium-sparing diuretics | Adjust or monitor | Hyperkalemia. | Monitor potassium. |
| CYP2C9 substrates or inhibitors (phenytoin, amiodarone, miconazole) | Minor | Possible interaction via CYP2C9. | Monitor. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Dyspepsia, abdominal pain, nausea, diarrhea
- Dizziness
Serious
- Gastrointestinal bleeding, ulceration, perforation
- Myocardial infarction and stroke (diclofenac-like risk)
- Kidney failure, nephrotic syndrome, interstitial nephritis
- Hepatitis
- Anaphylaxis; Stevens-Johnson syndrome, toxic epidermal necrolysis
Monitoring parameters
- Kidney function regularly in mild to moderate impairment, heart failure, liver disease, diuretic use, after major surgery and in older adults; blood pressure; potassium with potassium-sparing diuretics; gastrointestinal bleeding (SmPC 4.4). Check creatinine and potassium within 1–2 weeks of starting in CKD or with an ACE inhibitor, ARB, mineralocorticoid receptor antagonist (MRA) or diuretic; avoid the NSAID + ACE inhibitor/ARB + diuretic ("triple whammy") combination and long-term use in CKD. Kidney
- Creatinine and potassium within 1–2 weeks of starting in CKD or with an ACE inhibitor, ARB, mineralocorticoid receptor antagonist or diuretic; avoid long-term use in CKD
- Kidney function regularly in CKD
- Blood pressure
- Gastrointestinal bleeding
Pharmacokinetics
Key PK parameters
| Bioavailability | Almost 100% |
|---|---|
| Time to peak | 1.25 to 3 hours |
| Half-life | 4 to 4.3 hours |
| Half-life in kidney failure (ESKD) kidney | No clinically significant change in mild to moderate impairment (single dose); severe not studied |
| Volume of distribution | About 30 L |
| Protein binding | Over 99.7% |
| Metabolism (CYP, transporters) | Mainly CYP2C9 to 4'-OH-aceclofenac; diclofenac formed |
| Active metabolites | Diclofenac (minor) |
| Renal excretion kidney | About two-thirds in urine as metabolites; 1% unchanged |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Swedish Medical Products Agency. Barcan 100 mg film-coated tablets SmPC (English) [MPA (Sweden) product information, March 24, 2023; no US FDA label]. https://docetp.mpa.se/LMF/Barcan%20film-coated%20tablet%20ENG%20SmPC_09001bee807a07bc.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Almirall, S.A. (2023). Barcan 100 mg film-coated tablets (aceclofenac) [Summary of product characteristics, English; revised March 24, 2023]. Swedish Medical Products Agency (Läkemedelsverket). https://docetp.mpa.se/LMF/Barcan%20film-coated%20tablet%20ENG%20SmPC_09001bee807a07bc.pdf
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .